Genotyping K-RAS and EGFR in Greek Non-small-cell Lung Cancer Patients: Incidence, Significance and Treatment Implications
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Non Small Cell Lung Cancer
- Sponsor
- Hellenic Cooperative Oncology Group
- Enrollment
- 424
- Locations
- 1
- Primary Endpoint
- Progression free survival
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
Retrospective analysis where patients with histologically confirmed Non-small cell lung cancer (NSCLC) were centrally evaluated for the presence of KRAS and EGFR mutations.
Detailed Description
A retrospective analysis, performed by the Hellenic Co-operative Oncology Group (HeCOG), in samples from patients with histologically confirmed NSCLC, who had been treated within HeCOG-affiliated centres from March 2000 through December 2012, were centrally evaluated for the presence of KRAS and EGFR mutations. All patients had available clinicopathological data at diagnosis. Formalin-fixed, paraffin-embedded tissue blocks were retrospectively retrieved from the HeCOG tumor repository. Cytologic material was prospectively submitted for genotyping in more recent years (2010-2012).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with histologically confirmed NSCLC
- •Signed and dated written informed consent
- •Age 18 years
- •Available cytological material
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Progression free survival
Time Frame: from the date of treatment start until verified disease progression, death from any cause or date of last contact whichever occurred first, up to 9 months
Overall survival
Time Frame: from the date of treatment start until verified disease progression, death from any cause or date of last contact whichever occurred first, up to 36 months